Fraunhofer IZI strengthens contacts to South Korea

21.2.2019

On February 20, 2019, the Fraunhofer Institute for Cell Therapy and Immunology IZI and the South Korean Korea Drug Development Fund (KDDF) signed a Memorandum of Understanding. By this both institutions confirm their willingness to cooperate in the future.

Signing of the Memorandum of Understanding by Taeerk Kim (CBO KDDF) and Dr. Thomas Tradler (Fraunhofer IZI)
© KDDF

Signing of the Memorandum of Understanding by Taeerk Kim (CBO KDDF) and Dr. Thomas Tradler (Fraunhofer IZI)

With the Memorandum of Understanding, the Leipzig-based Fraunhofer institute and the South Korean KDDF confirm their commitment to a future close cooperation. The KDDF will support Fraunhofer IZI in the identification and subsequent cooperation with South Korean pharmaceutical companies. Fraunhofer IZI will support KDDF and South Korean pharmaceutical companies in finding German cooperation partners and in other activities in Germany. KDDF is a Korean Governmental Agency aiming at transgovernmental support of drug development in Korea, a consortium of three health care-related Ministries of Korean government (Ministry of Science, ICT, and Future Planning, Ministry of Trade, Industry & Energy, and Ministry of Health and Welfare).
    
The signing ceremony of the Memorandum of Understanding between Fraunhofer IZI and KDDF took place on the margins of KDDF's 3rd Global Connection & Development Tech Fair Conference in Seoul. Dr. Thomas Tradler, MBA, Head of Business Development at Fraunhofer IZI, was invited speaker at the conference. This year‘s Tech Fair was opened by Taeerk Kim, CBO of KDDF. More than 270 guests, mostly representatives of the South Korean pharmaceutical industry, attended the event.